You are here: Welcome » COVID-19 Vaccines » Novavax NVX-CoV2373

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Both sides next revision
covid-19_vaccines:nvx-cov2373 [2022/02/03 22:13]
brian [Clinical Trials] 		covid-19_vaccines:nvx-cov2373 [2022/03/31 09:19] (current)
mathew
Line 1: Line 1:
-===== Novavax NVX-CoV2373 =====+====== Novavax NVX-CoV2373 ======
  
-NVX-CoV2373 is a protein subunit vaccine for Covid-19 from Novavax. It was the first protein sub-unit vaccine to be approved in Europe or the USA.+**NVX-CoV2373** is a protein subunit vaccine for Covid-19 from [[:Pharmaceutical corporations:Novavax|Novavax]]. It was the first protein sub-unit vaccine to be approved in Europe or the USA.
  
 NVX-CoV2373 is engineered from the genetic sequence of the first strain of SARS-CoV-2. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate.  NVX-CoV2373 is engineered from the genetic sequence of the first strain of SARS-CoV-2. NVX-CoV2373 was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate. 
Line 11: Line 11:
 Funded, in part, by Operation Warp Speed (OWS). Funded, in part, by Operation Warp Speed (OWS).
  
 +===== Patent =====
 +Patent: [[https://patents.google.com/patent/US20210228709A1|US20210228709A1]]
  
 +2020-01-27
 +Priority to US202062966271P
  
-==== Pre-Clinical ====+2021-03-18 
 +Application filed by Novavax Inc 
 + 
 +2021-07-29 
 +Publication of US20210228709A1 
 + 
 +2022-02-22 
 +Application granted 
 + 
 +2022-02-22 
 +Publication of US11253586B2 
 + 
 +Status 
 +Active 
 +2040-08-19 
 + 
 +Anticipated expiration 
 + 
 +===== Pre-Clinical =====
  
 SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice((https://www.nature.com/articles/s41467-020-20653-8)) SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice((https://www.nature.com/articles/s41467-020-20653-8))
-==== Clinical Trials ====+ 
 +===== Clinical Trials =====
  
 **Clinical Trial Phase I/II:**  **Clinical Trial Phase I/II:** 
Line 28: Line 51:
   * Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant((https://www.nejm.org/doi/full/10.1056/NEJMoa2103055))   * Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant((https://www.nejm.org/doi/full/10.1056/NEJMoa2103055))
  
-==== Authorizations ====+===== Authorizations =====
 November 1, 2021: Indonesia((https://ir.novavax.com/2021-11-01-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indonesia)) \\ November 1, 2021: Indonesia((https://ir.novavax.com/2021-11-01-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indonesia)) \\
 November 17, 2021: Philippines((https://ir.novavax.com/2021-11-17-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-the-Philippines)) \\ November 17, 2021: Philippines((https://ir.novavax.com/2021-11-17-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-the-Philippines)) \\
Back to top